Drug class profile · refreshed daily from federal data

Benzodiazepine

22 molecules in this class, $638.0M combined CY2024 Part D spend across 51.3M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Benzodiazepine class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 22tracked in Part D
CY24 Part D spend: $638.0Mcombined across class
Total Rx claims: 51.3M12.4M unique beneficiaries
Generic mfrs (active): 94across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

01

Alprazolam

Brand: Xanax · 17.4M Part D claims (CY24) · 4.1M beneficiaries · First FDA approval: 1981-10-16

9 generic mfrs 99 plans require PA

Low NADAC$0.023

→

Avg plan cost$1.56

Part D spend $128.6M 69× spread, current vs floor

Class share

20%

of class CY24 spend

View profile →

02

Lorazepam

Brand: Ativan · 12.1M Part D claims (CY24) · 3.3M beneficiaries · First FDA approval: 1980-07-25

15 generic mfrs 328 plans require PA Active FDA shortage

Low NADAC$0.033

→

Avg plan cost$1.13

Part D spend $123.2M 35× spread, current vs floor

Class share

19%

of class CY24 spend

View profile →

03

Clonazepam

Brand: Klonopin · 13.2M Part D claims (CY24) · 2.4M beneficiaries · First FDA approval: 1975-06-02

11 generic mfrs 56 plans require PA Active FDA shortage

Low NADAC$0.020

→

Avg plan cost$0.308

Part D spend $113.3M 15× spread, current vs floor

Class share

18%

of class CY24 spend

View profile →

04

Clobazam

Brand: Onfi · 285K Part D claims (CY24) · 44K beneficiaries · First FDA approval: 2012-12-14

14 generic mfrs 1396 plans require PA

Low NADAC$0.161

→

Avg plan cost$7.23

Part D spend $82.4M 45× spread, current vs floor

Class share

13%

of class CY24 spend

View profile →

05

Diazepam

Brand: Valium · 4.5M Part D claims (CY24) · 1.6M beneficiaries · First FDA approval: 1963-11-15

16 generic mfrs 965 plans require PA

Low NADAC$0.022

→

Avg plan cost$90.66

Part D spend $75.9M 4095× spread, current vs floor

Class share

12%

of class CY24 spend

View profile →

06

Midazolam

Brand: MIDAZOLAM · 100K Part D claims (CY24) · 65K beneficiaries · First FDA approval: 2000-06-20

9 generic mfrs 89 plans require PA Active FDA shortage

Low NADAC$0.231

→

Avg plan cost$22.27

Part D spend $58.3M 97× spread, current vs floor

Class share

9%

of class CY24 spend

View profile →

07

Temazepam

Brand: RESTORIL · 3.3M Part D claims (CY24) · 664K beneficiaries · First FDA approval: 1981-02-27

7 generic mfrs 279 plans require PA

Low NADAC$0.079

→

Avg plan cost$0.469

Part D spend $41.1M 6× spread, current vs floor

Class share

6%

of class CY24 spend

View profile →

08

Estazolam

95K Part D claims (CY24) · 19K beneficiaries · First FDA approval: 1997-10-01

3 generic mfrs 8 plans require PA

Low NADAC$0.786

→

Avg plan cost$0.806

Part D spend $5.7M 1× spread, current vs floor

Class share

1%

of class CY24 spend

View profile →

09

Triazolam

Brand: Halcion · 155K Part D claims (CY24) · 78K beneficiaries · First FDA approval: 1982-11-15

2 generic mfrs 14 plans require PA Discontinued

Low NADAC$0.340

→

Avg plan cost$0.346

Part D spend $5.3M 1× spread, current vs floor

Class share

1%

of class CY24 spend

View profile →

10

Oxazepam

47K Part D claims (CY24) · 10K beneficiaries · First FDA approval: 2007-01-02

4 generic mfrs 69 plans require PA

Low NADAC$0.688

→

Avg plan cost$0.951

Part D spend $2.7M 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

11

Chlordiazepoxide

145K Part D claims (CY24) · 44K beneficiaries · First FDA approval: 1976-06-15

3 generic mfrs 30 plans require PA

Low NADAC$0.142

→

Avg plan cost$0.164

Part D spend $1.5M 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

12

Alprazolam C-Iv

— Part D claims (CY24) · First FDA approval: 2023-03-14

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

13

Alprazolam Odt C-Iv

— Part D claims (CY24) · First FDA approval: 2025-08-22

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

14

Chlordiazepoxide and Amitriptyline

— Part D claims (CY24) · First FDA approval: 1986-12-10

1 generic mfrs 14 plans require PA

Low NADAC$1.20

→

Avg plan cost$1.39

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

15

Chlordiazepoxide and Clidinium

Brand: Librax · — Part D claims (CY24) · First FDA approval: 1966-09-01

Brand-only (no generics)

Low NADAC$0.269

→

Avg plan cost$0.269

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

16

Diazepam Intensol

— Part D claims (CY24) · First FDA approval: 1987-04-03

Brand-only (no generics) 157 plans require PA

Low NADAC$0.997

→

Avg plan cost$0.997

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

17

Diazepam Oral

Brand: Diazepam · — Part D claims (CY24) · First FDA approval: 2016-06-24

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

18

Diazepam Oral Solution (Concentrate)

Brand: Diazepam · — Part D claims (CY24) · First FDA approval: 2014-04-14

Brand-only (no generics)

Low NADAC$0.997

→

Avg plan cost$0.997

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

19

Midazolam In

— Part D claims (CY24) · First FDA approval: 2025-10-15

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

20

Midazolam Injection,

— Part D claims (CY24) · First FDA approval: 2022-08-08

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

21

Quazepam

— Part D claims (CY24) · First FDA approval: 2018-03-20

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

22

Temazepam Civ

Brand: Temazepam · — Part D claims (CY24) · First FDA approval: 1990-09-30

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

Related questions.

Q&A librarySourced · reviewed quarterly

pricingWhat is NADAC?pricingIs NADAC the same as my PBM cost?pricingWhat is spread pricing?pricingWhat is a NADAC pass-through PBM contract?pricingWhat's the difference between AWP, MAC, and NADAC?pricingWhat is a dispensing fee in a PBM contract?

Browse all canonical questions →